William Blair Investment Management LLC Boosts Holdings in Haemonetics Co. (NYSE:HAE)

William Blair Investment Management LLC raised its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 29.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 446,258 shares of the medical instruments supplier's stock after purchasing an additional 101,807 shares during the quarter. William Blair Investment Management LLC owned 0.89% of Haemonetics worth $34,844,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust raised its position in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the period. AlphaQuest LLC raised its position in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after acquiring an additional 1,826 shares during the period. KBC Group NV raised its position in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares during the period. iSAM Funds UK Ltd acquired a new position in shares of Haemonetics in the third quarter worth about $204,000. Finally, HighTower Advisors LLC raised its position in shares of Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 244 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Haemonetics Price Performance

HAE stock traded down $0.16 during mid-day trading on Friday, reaching $64.08. The company's stock had a trading volume of 887,916 shares, compared to its average volume of 649,971. The stock has a market cap of $3.22 billion, a PE ratio of 25.23, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97. The company's 50 day moving average is $67.29 and its two-hundred day moving average is $75.03.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities research analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on HAE shares. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an "overweight" rating and a $116.00 price objective for the company. Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price target for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Raymond James restated a "strong-buy" rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Finally, Needham & Company LLC reduced their price target on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Haemonetics presently has an average rating of "Moderate Buy" and a consensus price target of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.